Zippi-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The synergistic action of these two agents in Zippi-DSR Capsule offers comprehensive treatment by addressing both delayed gastric emptying and excessive acid production. This combination is particularly beneficial in patients presenting with dyspeptic symptoms accompanied by acid reflux. Zippi-DSR Capsule should be administered as prescribed by a healthcare professional, taking into account the patient’s medical history and concomitant medications to avoid potential drug interactions. Common side effects may include headache, dry mouth, and abdominal discomfort. Use is contraindicated in patients with hypersensitivity to either component or in those with underlying cardiac conditions associated with Domperidone.